Antipa Minerals Ltd (ASX:AZY) Retains 100% Ownership of Paterson Project
Antipa Minerals Ltd (ASX:AZY) retains full ownership of the Paterson Project, consolidating its Paterson Province tenement package.
Category: Companies
4DMedical Limited (ASX:4DX) Secures New Industry Contracts and Gains Congressional Recognition
4DMedical Limited (ASX:4DX) wins new industry contracts and is highlighted in US Congressional testimony on VA Healthcare modernization.
Riversgold Limited (ASX:RGL) Reports High Chargeability in Sulphide Samples
Riversgold Limited (ASX:RGL) announces high chargeability results for sulphide samples, validating Drone MobileMT for the Saint John Project.
Global Lithium Resources Limited (ASX:GL1) Strengthens Partnership with Canmax on Manna Project
Global Lithium Resources Limited (ASX:GL1) varies its offtake agreement with Canmax, reinforcing support for the Manna Lithium Project.
Cauldron Energy Limited (ASX:CXU) Expands Yanrey Project with Six Tenement Acquisition
Cauldron Energy (ASX:CXU) acquires six tenements at Yanrey and announces maiden Mineral Resource Estimate for Manyingee South Deposit.
Firetail Resources (ASX:FTL) Updates on Picha Copper Project Exploration
Firetail Resources (ASX:FTL) reports ongoing exploration and upcoming drilling activities at its Picha Copper Project in Peru.
Silk Logistics Holdings (ASX:SLH) Announces ACCC Pauses Review Timeline
Silk Logistics Holdings (ASX:SLH) updates investors on ACCC pausing the review of its acquisition by DP World Australia, with the scheme meeting set for June 2025.
Osteopore Limited (ASX:OSX) Secures EU MDR Approval for Custom Implants
Osteopore (ASX:OSX) secures EU MDR approval for custom orthopaedic and cranial implants, expanding its market in Europe.
Bayan Mining and Minerals Limited (ASX:BMM) Secures IP License for Solar Cell Recycling Technology
Bayan Mining (ASX:BMM) licenses Macquarie University’s innovative microwave technology for sustainable solar panel recycling.
Nyrada Inc. (ASX:NYR) Progresses Phase I Clinical Trial
Nyrada Inc. (ASX:NYR) advances its Phase I clinical trial to the second cohort, anticipating final readouts in Q3 CY2025.